Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 82

Similar articles for PubMed (Select 17909383)

1.
2.

Comparative effectiveness research methods: symposium overview and summary.

Lohr KN.

Med Care. 2010 Jun;48(6 Suppl):S3-6. doi: 10.1097/MLR.0b013e3181e10434.

PMID:
20473188
3.
4.

Utilizing Medicare claims data for realā€time drug safety evaluations:is it feasible?

Hartzema AG, Racoosin JA, MaCurdy TE, Gibbs JM, Kelman JA.

Pharmacoepidemiol Drug Saf. 2011 Jul;20(7):684-8.

PMID:
21847800
5.
6.

Evaluating the patient safety indicators: how well do they perform on Veterans Health Administration data?

Rosen AK, Rivard P, Zhao S, Loveland S, Tsilimingras D, Christiansen CL, Elixhauser A, Romano PS.

Med Care. 2005 Sep;43(9):873-84.

PMID:
16116352
8.

Developments in post-marketing comparative effectiveness research.

Schneeweiss S.

Clin Pharmacol Ther. 2007 Aug;82(2):143-56. Epub 2007 Jun 6. Review.

9.
10.

Relevance of the Agency for Healthcare Research and Quality Patient Safety Indicators for children's hospitals.

Sedman A, Harris JM 2nd, Schulz K, Schwalenstocker E, Remus D, Scanlon M, Bahl V.

Pediatrics. 2005 Jan;115(1):135-45. Epub 2004 Dec 3.

PMID:
15579669
11.

Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data.

Nelson JC, Cook AJ, Yu O, Dominguez C, Zhao S, Greene SK, Fireman BH, Jacobsen SJ, Weintraub ES, Jackson LA.

Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:62-71. doi: 10.1002/pds.2324.

PMID:
22262594
12.

Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system.

Rassen JA, Schneeweiss S.

Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:41-9. doi: 10.1002/pds.2328.

PMID:
22262592
13.

Design considerations in an active medical product safety monitoring system.

Gagne JJ, Fireman B, Ryan PB, Maclure M, Gerhard T, Toh S, Rassen JA, Nelson JC, Schneeweiss S.

Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:32-40. doi: 10.1002/pds.2316.

PMID:
22262591
14.

The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.

Platt R, Carnahan RM, Brown JS, Chrischilles E, Curtis LH, Hennessy S, Nelson JC, Racoosin JA, Robb M, Schneeweiss S, Toh S, Weiner MG.

Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:1-8. doi: 10.1002/pds.2343.

PMID:
22262586
15.
16.

The measurement and monitoring of surgical adverse events.

Bruce J, Russell EM, Mollison J, Krukowski ZH.

Health Technol Assess. 2001;5(22):1-194. Review.

17.

Potential use of routine databases in health technology assessment.

Raftery J, Roderick P, Stevens A.

Health Technol Assess. 2005 May;9(20):1-92, iii-iv. Review.

18.

Signal detection methodologies to support effective safety management.

van Manen RP, Fram D, DuMouchel W.

Expert Opin Drug Saf. 2007 Jul;6(4):451-64. Review.

PMID:
17688389
19.

Active surveillance of postmarket medical product safety in the Federal Partners' Collaboration.

Robb MA, Racoosin JA, Worrall C, Chapman S, Coster T, Cunningham FE.

Med Care. 2012 Nov;50(11):948-53. doi: 10.1097/MLR.0b013e31826c874d.

PMID:
23047784
20.

Postmarketing evaluations help determine contraceptive safety, efficacy.

[No authors listed]

Netw Res Triangle Park N C. 1988 Winter;9(2):1-2, 7.

PMID:
12280950
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk